Cadrenal Therapeutics, Inc. CVKD
Set alert
As of Nov 3, 10:03 AM ET
- YTD
- -84.07%
- 1 year
- -91.99%
- Open
- 1.05
- Prev close
- 1.04
- Mkt cap
- 3.89M
- Vol
- 4.09K
- Avg vol
- 473.07K
- EPS
- -4.91
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.05
- High
- 1.10
- Forward P/E
- -3.02
- Beta
- 0.00
- Short ratio
- 1.17
- Inst. own
- 4.75%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 14.77
- 200-d avg
- 9.61
- 1y target
- 35.67
5D chart
Signals (62)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 3:30 PM | 18 hours ago |
| SMA: Bullish | Nov 2, 3:05 PM | 19 hours ago |
| SMA: Bearish | Nov 2, 12:25 PM | 21 hours ago |
| MACD: Sell Signal | Nov 2, 12:10 PM | 22 hours ago |
| RSI: Overbought | Nov 2, 10:40 AM | 23 hours ago |
| SMA: Bullish | Nov 2, 9:40 AM | 1 day ago |
| SMA: Bullish | Nov 2, 9:40 AM | 1 day ago |
| SMA: Bearish | Nov 2, 9:30 AM | 1 day ago |
| SMA: Bearish | Nov 2, 9:30 AM | 1 day ago |
| SMA: Bullish | Oct 30, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:35 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:25 PM | 3 days ago |
Newest 20 of 62.
News
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 203.8% to $3.19 during Tuesday's regular session. The company's market cap stands at $2.6 million. Picard Medical (AMEX:PMI) stock…
3 weeks ago globenewswire.com
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
PONTE VEDRA, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) (“Cadrenal” or the “Company”), a late-stage biopharmaceutical company advancing novel therapies for…
1 month ago globenewswire.com
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
PONTE VEDRA, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology…
2 months ago globenewswire.com
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
PONTE VEDRA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday's pre-market session. The company's market cap stands at $7.0 million. Aligos Therapeutics (NASDAQ:ALGS)…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Intelligent Bio Solutions (NASDAQ:INBS) stock moved upwards by 8.2% to $2.63 during Tuesday's after-market session. The company's market cap stands at $7.2 million. Jaguar Health…
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regular session. The company's market cap stands at $2.7 million. USBC (AMEX:USBC) stock moved upwards by…
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 68.4% to $7.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.7 million. Lakewood-Amedex…
2 months ago benzinga.com
Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Shares of Pyxis Tankers Inc (NASDAQ:PXS) rose sharply in pre-market trading after the company reported better-than-expected earnings for the second quarter. The company posted quarterly earnings of…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Redhill Biopharma (NASDAQ:RDHL) stock increased by 69.4% to $1.12 during Monday's regular session. The company's market cap stands at $4.0 million. CollPlant Biotechnologies (NASDAQ:CLGN)…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Redhill Biopharma (NASDAQ:RDHL) shares increased by 96.7% to $1.3 during Monday's pre-market session. The market value of their outstanding shares is at $4.0 million. Vivos Therapeutics…
-
2 months ago benzinga.com
Cadrenal Therapeutics Announces FDA's Feedback At Type D Meeting For CAD-1005 Inhibitor To Treat Heparin-Induced Thrombocytopenia
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced…
2 months ago globenewswire.com
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the…
2 months ago globenewswire.com
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding Late-breaking…
-
3 months ago benzinga.com
Cadrenal Therapeutics Consolidates Multi-Indication Strategy For Cardiac Acute Critical Care Franchise, With Focus On CAD-1005 For Both HIT And CSA-AKI
Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes…
3 months ago globenewswire.com
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation
Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes…
-
3 months ago benzinga.com
Cadrenal Therapeutics Unveils Cardiac Critical Care Franchise, Seeks Partners For Late-Stage Cardiovascular Assets
Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditionsCompany is exploring development, licensing, and…
3 months ago globenewswire.com
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions Company is exploring development, licensing, and…
-
3 months ago benzinga.com
Cadrenal Therapeutics’ Late-Breaking Clinical Data From Phase 2 Study Of 12-LOX Inhibitor CAD-1005 Featured In Oral Presentation At ISTH 2026 Congress
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in…
3 months ago globenewswire.com
Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in…
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Seer (NASDAQ:SEER) shares rose 32.1% to $2.14 during Monday's pre-market session. The market value of their outstanding shares is at $89.0 million. Innovative Eyewear (NASDAQ:LUCY) stock rose…
4 months ago globenewswire.com
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon the exercise in full of warrants
-
4 months ago benzinga.com
Cadrenal Therapeutics Says Late-Breaking Clinical Data On 12-Lipoxygenase Inhibitor, CAD-1005, Accepted For Oral Presentation At 34th Congress Of ISTH
Selection highlights the clinical value potential of Cadrenal’s first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT)First-ever randomized, blinded, placebo-controlled…
4 months ago globenewswire.com
Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
Selection highlights the clinical value potential of Cadrenal's first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT) First-ever randomized, blinded, placebo-controlled…
-
4 months ago benzinga.com
Cadrenal Therapeutics Plans To Submit An FDA Rare Pediatric Disease Designation Request For Tecarfarin As A Treatment For Pediatric Patients With Kawasaki Disease And Coronary Artery Aneurysms Who Need Chronic Oral Anticoagulation
Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to global pharmaceutical partners at the 2026 BIO International Convention in San DiegoKawasaki…
4 months ago globenewswire.com
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to global pharmaceutical partners at the 2026 BIO International Convention in San Diego Kawasaki…
-
4 months ago benzinga.com
Cadrenal Therapeutics Plans To Initiate Phase 2a Proof-Of-Concept Clinical Trial Of CAD-1005, Being Studied To Prevent Acute Kidney Injury In High-Risk Patients Undergoing Cardiac Surgery
New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussionsAdditional billion-dollar target- Cardiac Surgery-Associated…
4 months ago globenewswire.com
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussions Additional billion-dollar target- Cardiac Surgery-Associated…
-
5 months ago benzinga.com
Cadrenal Therapeutics Announces Participation In BIO 2026; To Host Partnering Meetings To Discuss Development And Commercialization Opportunities For Differentiated Pipeline, Headlined By CAD-1005 And Tecarfarin
Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential12-LOX…
5 months ago globenewswire.com
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential 12-LOX…
5 months ago globenewswire.com
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and…
-
6 months ago benzinga.com
Cadrenal Therapeutics Q1 EPS $(1.04) Beats $(1.62) Estimate
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.04) per share which beat the analyst consensus estimate of $(1.62) by 35.8 percent. This is a 50.24 percent increase over losses…
6 months ago globenewswire.com
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and…
-
6 months ago benzinga.com
Cadrenal Therapeutics Receives FDA Guidance For Phase 3 Trial Of CAD-1005 Heparin-Induced Thrombocytopenia Treatment
Cadrenal has completed its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005.The meeting…
6 months ago globenewswire.com
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
6 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Lowers Price Target to $13
HC Wainwright & Co. analyst Joseph Pantginis maintains Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and lowers the price target from $32 to $13.
-
7 months ago benzinga.com
Cadrenal Therapeutics Q4 EPS $(1.41) Misses $(1.18) Estimate
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(1.18) by 19.49 percent. This is a 49.64 percent increase over…
7 months ago globenewswire.com
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal's near-term development priority; broader 12-LOX platform remains a longer-term opportunity…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
7 months ago benzinga.com
Cadrenal Therapeutics Highlights Recent Scientific Findings Demonstrating Potential Of 12-Lipoxygenase Inhibitor, CAD-1005, To Target Inflammatory Consequences Of Obesity And Type 2 Diabetes
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thrombotic conditions, today highlighted recent scientific…
7 months ago globenewswire.com
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and…
-
8 months ago benzinga.com
Cadrenal Therapeutics Data From Phase 2 Trial Of CAD-1005 Demonstrates Reduction In Thrombotic Events
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing therapies for life-threatening immune and thrombotic disorders, today provided additional perspectives on…
8 months ago globenewswire.com
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla.,…
8 months ago defenseworld.net
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD - Get Free Report) was the target of a significant decrease in short interest in the month of February. As of February 13th, there was short interest…
-
8 months ago benzinga.com
Cadrenal Therapeutics Announces Data From Phase 2 Study Of CAD-1005 Shows Over 25% Absolute Reduction In Thrombotic Events; CAD-1005 Failed To Significantly Impact Platelet Recovery Rate
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced encouraging results…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session